LAVA Therapeutics (LVTX) Short Interest Ratio & Short Volume

Short interest is the volume of LAVA Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 118,500 shares of LVTX short. 0.84% of LAVA Therapeutics' shares are currently sold short. Learn More on LAVA Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.84% of LAVA Therapeutics' floating shares are currently sold short.

LAVA Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 118,500 shares, a drop of 2.3% from the previous total of 121,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

LAVA Therapeutics currently has issued a total of 0 shares. Some of LAVA Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. LAVA Therapeutics currently has a public float of 14,120,000 shares.

0.84% of LAVA Therapeutics' shares are currently sold short. Here is how the short interest of companies compare to LAVA Therapeutics: Mainz Biomed (1.75%), NLS Pharmaceutics Ltd. (0.18%), Pharvaris (0.66%), Procaps Group S.A. (0.07%), Qilian International Holding Group Limited (0.68%), Adicet Bio, Inc. (8.45%), Shattuck Labs, Inc. (3.85%), Editas Medicine, Inc. (25.24%), Eli Lilly and Company (0.64%), Novo Nordisk A/S (0.08%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

Short selling LVTX is an investing strategy that aims to generate trading profit from LAVA Therapeutics as its price is falling. LVTX shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for LAVA Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of LVTX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LVTX, twice per month. The most recent reporting period available is May, 15 2024.